Dotinurad, a URAT1-selective inhibitor, remarkably attenuates these detrimental impacts of diet-induced metabolic heart disease and may be a potential therapeutic agent for metabolic heart disease-associated hyperuricemia (Graphical Abstract). This evidence concerns the gene SLC22A12 and hyperuricemia.